Medtronic plc, one of the world’s leading healthcare technology firms, announced on Tuesday its plan to separate its Diabetes business into a standalone company, tentatively titled the New Diabetes Company. The move marks a strategic shift aimed at sharpening Medtronic’s focus on high-margin, innovation-driven growth sectors, while enabling the Diabetes division to flourish as an independent entity dedicated solely to insulin management solutions.
According to the announcement, the separation will be executed through a series of capital markets transactions, with the preferred route being an initial public offering (IPO), followed by a split-off. Medtronic anticipates completing the process within 18 months, subject to market and regulatory conditions.
“This marks a significant milestone in driving both Medtronic and the Diabetes business to achieve lasting value for Medtronic, our shareholders, customers, and patients,” said Geoff Martha, chairman and CEO of Medtronic. “Active portfolio management is an important lever to delivering on our ongoing growth and success, and this decision shifts the Medtronic portfolio to have intense focus on our highest margin growth drivers where we have our strongest core competencies.”
A Strategic Split to Unlock Value
The decision is rooted in Medtronic’s broader strategy to streamline its operations and capitalize on its strongest areas, including pulsed field ablation, renal denervation, implantable tibial neuromodulation, and soft tissue robotics. By spinning off the Diabetes business, which currently represents 8% of Medtronic’s revenue and 4% of its segment operating profit, the company expects to boost its adjusted gross margin by approximately 50 basis points and operating margin by about 100 basis points. The move is also projected to be immediately accretive to Medtronic’s adjusted earnings per share (EPS).
For shareholders, the transaction presents a potential value unlock. The spin-off is expected to be tax-free for U.S. federal income tax purposes, and Medtronic aims to retire shares without impacting its cash reserves, reducing dividend liabilities while preserving its current dividend per share.
New Diabetes Company: A Focused Vision
The newly formed New Diabetes Company will emerge as a direct-to-consumer leader in insulin management. It will be uniquely positioned as the only company offering a fully integrated ecosystem for intensive insulin therapy, which includes both Automated Insulin Delivery (AID) systems and Smart Multiple Daily Injection (MDI) solutions.
Currently employing over 8,000 people globally, the Diabetes unit brings with it a well-established commercial network, proprietary product pipeline, manufacturing operations, and regulatory infrastructure. Que Dallara, currently Executive Vice President and President of Medtronic Diabetes, has been named CEO of the New Diabetes Company.
“As we embark on this exciting new chapter, we celebrate the tireless efforts and dedication of our teams,” said Dallara. “Their passion and perseverance have brought us to this pivotal moment. Together, we’re poised to transform lives, giving people the freedom to forget diabetes and live their best lives.”
Dallara also expressed her appreciation for Medtronic’s leadership, adding, “I’m incredibly grateful to Geoff for his vision and commitment to investing in the Diabetes business, we wouldn’t be where we are without his unwavering support.”
